Sunshine Biopharma, Inc. (SBFM) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sunshine Biopharma Inc. experienced a significant year with a 14% average quarterly sales growth in 2023, reaching $24.09 million, partly due to the acquisition of Nora Pharma. The company also decreased its loss per share from $1.76 to $0.19 and furthered the development of two proprietary drugs. Despite challenges, like halting studies on an anticancer compound, Sunshine Biopharma is optimistic about continuing growth and profitability.
For further insights into SBFM stock, check out TipRanks’ Stock Analysis page.